<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800692</url>
  </required_header>
  <id_info>
    <org_study_id>H00012734</org_study_id>
    <secondary_id>R21AG067376-01A1</secondary_id>
    <nct_id>NCT04800692</nct_id>
  </id_info>
  <brief_title>The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication</brief_title>
  <acronym>ATLAS</acronym>
  <official_title>The Effects of ATLAS (Arginine Tetrahydrobiopterin L-Ascorbate) Therapy on Nitric Oxide Bioavailability and Pain-free Walking in Patients With Intermittent Claudication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will focus on people with claudication from peripheral arterial disease. The&#xD;
      investigators are researching whether a multicomponent therapeutic can increase the&#xD;
      production of Nitric Oxide in the blood and whether that leads to an improvement in pain free&#xD;
      walking distance and overall physical activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to show that ATLAS Therapy, (L-Arginine;&#xD;
      Tetrahydrobiopterin; L-Ascorbate) is bioavailable in humans and exerts a measurable effect on&#xD;
      its in vivo biological signature, Flow Mediated Vasodilation (FMD) in people with&#xD;
      intermittent claudication caused by peripheral arterial disease. This will be a Phase I /&#xD;
      dose finding study. All subjects will receive 2 different drug doses of the Kuvan the first&#xD;
      45 days they will receive 10 mg/kg/day. The second 45 days they will receive 20/mg/kg/day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects will receive the same starting dose of the 3 components which will be escalated at day 45.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nitric Oxide bioavailability</measure>
    <time_frame>90 days</time_frame>
    <description>Nitric Oxide bioavailability as measured by flow mediated dilatation (FMD).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Claudication, Intermittent</condition>
  <condition>Peripheral Artery Disease</condition>
  <condition>Peripheral Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Tetrahydrobiopterin Dose 1 (Day 0 to 44)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive 3300mg l-Ascorbate , l-Arginine 3400mg and 10mg/kg of Tetrahydrobiopterin once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetrahydrobiopterin Dose 2 (Day 45 to 90)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive 3300mg l-Ascorbate, l-Arginine 3400mg and 20mg/kg of Tetrahydrobiopterin once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrahydrobiopterin 10 mg/kg</intervention_name>
    <description>10mg/kg of Tetrahydrobiopterin daily.</description>
    <arm_group_label>Tetrahydrobiopterin Dose 1 (Day 0 to 44)</arm_group_label>
    <other_name>sapropterin</other_name>
    <other_name>kuvan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrahydrobiopterin 20 mg/kg</intervention_name>
    <description>20mg/kg of Tetrahydrobiopterin daily.</description>
    <arm_group_label>Tetrahydrobiopterin Dose 2 (Day 45 to 90)</arm_group_label>
    <other_name>sapropterin</other_name>
    <other_name>kuvan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Ascorbate</intervention_name>
    <description>3300 mg of l-ascorbate once daily</description>
    <arm_group_label>Tetrahydrobiopterin Dose 1 (Day 0 to 44)</arm_group_label>
    <arm_group_label>Tetrahydrobiopterin Dose 2 (Day 45 to 90)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Arginine</intervention_name>
    <description>3400mg of l-arginine once daily</description>
    <arm_group_label>Tetrahydrobiopterin Dose 1 (Day 0 to 44)</arm_group_label>
    <arm_group_label>Tetrahydrobiopterin Dose 2 (Day 45 to 90)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PAD as demonstrated by an ABI &lt;0 .9 in one leg or TBI less than &lt;0.7 in patients with&#xD;
             an ABI &gt;1.3 (non compressible vessels)&#xD;
&#xD;
          -  Rutherford Classification II, III&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  Willingness to discontinue phosphodiesterase (PDE) 5 inhibitors such as Viagra,&#xD;
             Cialis, Levitra, Revatio&#xD;
&#xD;
          -  Willingness to discontinue phosphodiesterase (PDE) 3inhibitors cilostazol, milrinone&#xD;
             or Vesnarinone&#xD;
&#xD;
          -  Willing and able to comply with all study procedures&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Sexually active subjects willing to use an acceptable method of contraception while&#xD;
             participating in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypotension defined as a systolic blood pressure less than 100mmhg systolic at&#xD;
             screening or baseline visit&#xD;
&#xD;
          -  Critical Leg Ischemia (Rutherford Classification IV, V, VI)&#xD;
&#xD;
          -  Surgical intervention to alleviate symptoms of claudication in the study leg within&#xD;
             the past 6 months or any endovascular interventions within 3 months or who is&#xD;
             scheduled to undergo surgical revascularization in the next 6 month&#xD;
&#xD;
          -  Walking limited by reasons other than claudication (e.g. arthritis, lung disease,&#xD;
             severe neuropathy, lower extremity amputation except single digits)&#xD;
&#xD;
          -  Serum creatinine &gt;1.5mg/dl or Hepatic enzymes &gt;2X the upper limit of normal&#xD;
&#xD;
          -  Serum potassium greater than 5.0 or use of a potassium sparing diuretic at screening&#xD;
&#xD;
          -  Pregnant, breast feeding or planning to become pregnant (subject or partner) at any&#xD;
             time during the study.&#xD;
&#xD;
          -  Myocardial Infarction, Cerebrovascular Accident or deep vein thrombosis within 12&#xD;
             months of screening&#xD;
&#xD;
          -  Known history of nephrolithiasis&#xD;
&#xD;
          -  History of ever having a seizure&#xD;
&#xD;
          -  Concurrent disease or condition that would interfere with study participation or&#xD;
             safety such as bleeding disorders, organ transplant, long term immunosuppression&#xD;
             (excluding inhaled steroids), current neoplasm or severe gastroesophageal reflux&#xD;
&#xD;
          -  History of vertigo or syncope within the past 10 years&#xD;
&#xD;
          -  Enrollment in another drug or device study within 30 days of screening&#xD;
&#xD;
          -  Required treatment with a drug known to inhibit folate metabolism (e.g. Methotrexate)&#xD;
&#xD;
          -  Taking any of the following medications; PDE3 Inhibitors, PDE5 inhibitors, trental,&#xD;
             nitrates, ginkgo biloba, levodopa, warfarin,&#xD;
&#xD;
          -  Axillary lymph node dissection&#xD;
&#xD;
          -  Presence of an amputation except single digits in either leg&#xD;
&#xD;
          -  Preexisting illness that limits ambulation such as severe COPD, class III-IV heart&#xD;
             failure, severe arthritis or back pain&#xD;
&#xD;
          -  Glucose-6-dehydrogenase deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis M Messina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMASS Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shauneen Valliere, MSN</last_name>
    <phone>508-856-1767</phone>
    <email>shauneen.valliere@umassmed.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mollynda McArthur, MS</last_name>
    <phone>508-856-2820</phone>
    <email>mollynda.mcarthur2@umassmed.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMASS Memorial Healthcare - University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shauneen Valliere, MSN</last_name>
      <phone>508-856-1767</phone>
      <email>shauneen.valliere@umassmed.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mollynda McArthur, MS</last_name>
      <phone>508-856-2820</phone>
      <email>mollynda.mcarthur2@umassmed.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Douglas Jones</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

